In the media – Autolomous receives loan from UK Research and Innovation to expedite the digitization of batch verification in cell and gene therapy manufacturing.

Our announcement has been picked up by PharmiWeb.com:

“Autolomous receives loan from UK Research and Innovation to expedite the digitization of batch verification in cell and gene therapy manufacturing

London, UK, May 4, 2021 – Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, today announces it has received a loan from UK Research and Innovation (UKRI), the public innovation agency, as part of the medicine’s manufacturing challenge.

The loan is provided as additional support for Autolomous to expedite development of AutoloMATE-Assist, its digital batch verification technology for cell and gene therapies (CGT). The project has commenced in April 2021 and is expected to last 24 months.

AutoloMATE-Assist is the third module from Autolomous’ digital platform AutoloMATE™. This is a business critical robust digital platform for efficiency, scalability and process streamlining of the GMP manufacturing and batch verification of cell & gene therapies. The other AutoloMATE modules are AutoloMATE-eBMR, which digitizes batch manufacturing records, and AutoloMATE-CLOCK that provides complete scheduling of all critical manufacturing variables. The three modules of the AutoloMATE platform will enable manufacturers of advanced therapies and cell and gene therapies to develop an end to end manufacturing strategy.”